| Literature DB >> 32413333 |
Michel Bernier1, Sarah J Mitchell2, Devin Wahl3, Antonio Diaz4, Abhishek Singh5, Wonhyo Seo6, Mingy Wang7, Ahmed Ali2, Tamzin Kaiser2, Nathan L Price5, Miguel A Aon8, Eun-Young Kim9, Michael A Petr2, Huan Cai10, Alessa Warren11, Clara Di Germanio2, Andrea Di Francesco2, Ken Fishbein10, Vince Guiterrez2, Dylan Harney12, Yen Chin Koay13, John Mach14, Ignacio Navas Enamorado2, Tamara Pulpitel15, Yushi Wang7, Jing Zhang7, Li Zhang7, Richard G Spencer10, Kevin G Becker16, Josephine M Egan10, Edward G Lakatta7, John O'Sullivan13, Mark Larance12, David G LeCouteur15, Victoria C Cogger15, Bin Gao6, Carlos Fernandez-Hernando5, Ana Maria Cuervo4, Rafael de Cabo17.
Abstract
Obesity is a top public health concern, and a molecule that safely treats obesity is urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatment for chronic alcohol addiction, exhibits anti-inflammatory properties and helps protect against certain types of cancer. Here, we show that in mice disulfiram treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on insulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy. Additionally, disulfiram treatment reversed established diet-induced obesity and metabolic dysfunctions in middle-aged mice. Reductions in feeding efficiency and increases in energy expenditure were associated with body weight regulation in response to long-term disulfiram treatment. Loss of fat tissue and an increase in liver fenestrations were also observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents, repurposing disulfiram in the clinic could represent a new strategy to treat obesity and its metabolic comorbidities. Published by Elsevier Inc.Entities:
Keywords: beta-cell hyperplasia; fibrosis; hepatic steatosis; inflammation; insulin resistance; obesity; weight gain
Year: 2020 PMID: 32413333 PMCID: PMC7957855 DOI: 10.1016/j.cmet.2020.04.019
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287